Kelli P Macdonald

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8833111/publications.pdf

Version: 2024-02-01

114 papers 9,544 citations

28274 55 h-index 94 g-index

116 all docs

116 does citations

116 times ranked

13360 citing authors

#	Article	IF	Citations
1	Donor bone marrow–derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice. Blood, 2022, 139, 1389-1408.	1.4	14
2	ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis. JHEP Reports, 2022, 4, 100386.	4.9	22
3	BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood, 2022, 139, 2983-2997.	1.4	6
4	Retinoic acid signaling acts as a rheostat to balance Treg function. , 2022, 19, 820-833.		8
5	Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. Transplantation and Cellular Therapy, 2022, 28, 426-445.	1.2	16
6	The liver contains distinct interconnected networks of <scp>CX3CR1</scp> ⁺ macrophages, <scp>XCR1</scp> ⁺ type 1 and <scp>CD301a</scp> ⁺ type 2 conventional dendritic cells embedded within portal tracts. Immunology and Cell Biology, 2022, 100, 394-408.	2.3	4
7	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. Blood, 2021, 137, 1090-1103.	1.4	8
8	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell, 2021, 184, 2167-2182.e22.	28.9	131
9	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: Ill. The 2020 Treatment of Chronic GVHD Report. Transplantation and Cellular Therapy, 2021, 27, 729-737.	1.2	29
10	Repopulating Microglia Promote Brain Repair in an IL-6-Dependent Manner. Cell, 2020, 180, 833-846.e16.	28.9	292
11	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood, 2020, 135, 28-40.	1.4	14
12	ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome. Cancer Immunology Research, 2020, 8, 1085-1098.	3.4	6
13	Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease. American Journal of Transplantation, 2019, 19, 1820-1830.	4.7	9
14	Expansion of IL-17A–secreting CD8+ mucosa-associated invariant T cells in peripheral blood following stem cell mobilization. Blood Advances, 2019, 3, 718-723.	5.2	7
15	Donor T-cell–derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract. Blood Advances, 2019, 3, 2859-2865.	5.2	21
16	Live imaging of collagen deposition during experimental hepatic schistosomiasis and recovery: a view on a dynamic process. Laboratory Investigation, 2019, 99, 231-243.	3.7	4
17	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood, 2019, 133, 94-99.	1.4	21
18	Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2. JCI Insight, 2019, 4, .	5.0	58

#	Article	IF	Citations
19	Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, S7-S14.	2.0	10
20	Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 19-26.	2.0	22
21	Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood, 2018, 132, 1675-1688.	1.4	119
22	Self-repopulating recipient bone marrow resident macrophages promote long-term hematopoietic stem cell engraftment. Blood, 2018, 132, 735-749.	1.4	69
23	Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Frontiers in Immunology, 2018, 9, 57.	4.8	46
24	Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. Blood, 2018, 131, 2651-2660.	1.4	113
25	Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. Journal of Clinical Investigation, 2018, 128, 1971-1984.	8.2	73
26	Acute graft-versus-host disease is regulated by an IL-17–sensitive microbiome. Blood, 2017, 129, 2172-2185.	1.4	63
27	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF- \hat{l}^2 production. Blood, 2017, 129, 2570-2580.	1.4	122
28	Acute myeloid leukemia stem cell function is preserved in the absence of autophagy. Haematologica, 2017, 102, e344-e347.	3.5	8
29	Eomesodermin promotes the development of type 1 regulatory T (T $<$ sub $>$ R $<$ /sub $>$ 1) cells. Science Immunology, 2017, 2, .	11.9	118
30	GVHD prevents NK-cell–dependent leukemia and virus-specific innate immunity. Blood, 2017, 129, 630-642.	1.4	32
31	Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood, 2017, 129, 13-21.	1.4	216
32	Harnessing bone marrow resident regulatory T cells to improve allogeneic stem cell transplant outcomes. International Journal of Hematology, 2017, 105, 153-161.	1.6	8
33	A Liver Capsular Network of Monocyte-Derived Macrophages Restricts Hepatic Dissemination of Intraperitoneal Bacteria by Neutrophil Recruitment. Immunity, 2017, 47, 374-388.e6.	14.3	171
34	An atypical role for the myeloid receptor Mincle in central nervous system injury. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2098-2111.	4.3	51
35	Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT. Blood Advances, 2017, 1, 341-351.	5.2	28
36	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight, 2017, 2, .	5.0	53

#	Article	IF	CITATIONS
37	Cytokine mediators of chronic graft-versus-host disease. Journal of Clinical Investigation, 2017, 127, 2452-2463.	8.2	74
38	Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. JCI Insight, 2016, 1, e86850.	5.0	43
39	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood, 2016, 127, 2144-2154.	1.4	145
40	Granzyme M has a critical role in providing innate immune protection in ulcerative colitis. Cell Death and Disease, 2016, 7, e2302-e2302.	6.3	14
41	Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. Blood, 2016, 128, 794-804.	1.4	49
42	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood, 2016, 128, 1013-1017.	1.4	95
43	Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions. Journal of Hepatology, 2016, 65, 758-768.	3.7	197
44	Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model. American Journal of Pathology, 2016, 186, 524-538.	3.8	28
45	Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects. Blood, 2015, 126, 1609-1620.	1.4	98
46	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood, 2015, 125, 4085-4094.	1.4	101
47	Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury. Fibrogenesis and Tissue Repair, 2015, 8, 19.	3.4	36
48	Lung parenchyma-derived IL-6 promotes IL-17A–dependent acute lung injury after allogeneic stem cell transplantation. Blood, 2015, 125, 2435-2444.	1.4	73
49	Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease. Journal of Experimental Medicine, 2015, 212, 1303-1321.	8.5	85
50	Imaging the immunological synapse between dendritic cells and T cells. Journal of Immunological Methods, 2015, 423, 40-44.	1.4	29
51	Autophagy is required for stem cell mobilization by G-CSF. Blood, 2015, 125, 2933-2936.	1.4	36
52	IL-17A–Producing γδT Cells Suppress Early Control of Parasite Growth by Monocytes in the Liver. Journal of Immunology, 2015, 195, 5707-5717.	0.8	25
53	Autophagy and haematopoietic stem cell transplantation. Immunology and Cell Biology, 2015, 93, 43-50.	2.3	8
54	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. Journal of Clinical Investigation, 2014, 124, 4867-4876.	8.2	173

#	Article	IF	Citations
55	Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncology, The, 2014, 15, 1451-1459.	10.7	194
56	Modification of T Cell Responses by Stem Cell Mobilization Requires Direct Signaling of the T Cell by G-CSF and IL-10. Journal of Immunology, 2014, 192, 3180-3189.	0.8	34
57	Origin of Langerhans cells in normal skin and chronic GVHD after hematopoietic stem-cell transplantation. Experimental Dermatology, 2014, 23, 75-77.	2.9	7
58	Selective organ specific inflammation in offspring harbouring microchimerism from strongly alloreactive mothers. Journal of Autoimmunity, 2014, 50, 51-58.	6.5	17
59	Cross-Dressing by Donor Dendritic Cells after Allogeneic Bone Marrow Transplantation Contributes to Formation of the Immunological Synapse and Maximizes Responses to Indirectly Presented Antigen. Journal of Immunology, 2014, 192, 5426-5433.	0.8	32
60	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood, 2014, 123, 3988-3998.	1.4	179
61	Type I IFN signaling in CD8– DCs impairs Th1-dependent malaria immunity. Journal of Clinical Investigation, 2014, 124, 2483-2496.	8.2	96
62	CSF-1–dependant donor-derived macrophages mediate chronic graft-versus-host disease. Journal of Clinical Investigation, 2014, 124, 4266-4280.	8.2	173
63	Induced Regulatory T Cells Promote Tolerance When Stabilized by Rapamycin and IL-2 In Vivo. Journal of Immunology, 2013, 191, 5291-5303.	0.8	101
64	Biology of Graft-versus-Host Responses: Recent Insights. Biology of Blood and Marrow Transplantation, 2013, 19, S10-S14.	2.0	47
65	PD-1 Dependent Exhaustion of CD8+ T Cells Drives Chronic Malaria. Cell Reports, 2013, 5, 1204-1213.	6.4	147
66	Absence of B Cells Does Not Compromise Intramembranous Bone Formation during Healing in a Tibial Injury Model. American Journal of Pathology, 2013, 182, 1501-1508.	3.8	16
67	Cytokines in graft-versus-host disease and graft-versus-leukemia. , 2013, , 357-391.		0
68	Smg1 haploinsufficiency predisposes to tumor formation and inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E285-94.	7.1	50
69	Promoting regulation via the inhibition of DNAM-1 after transplantation. Blood, 2013, 121, 3511-3520.	1.4	47
70	$CD8\hat{l}\pm + DCs$ can be induced in the absence of transcription factors Id2, Nfil3, and Batf3. Blood, 2013, 121, 1574-1583.	1.4	95
71	Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nature Medicine, 2012, 18, 135-142.	30.7	206
72	Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood, 2012, 119, 1810-1820.	1.4	562

5

#	Article	IF	CITATIONS
73	Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subsets. Blood, 2012, 119, 5918-5930.	1.4	32
74	Identification and expansion of highly suppressive CD8+FoxP3+ regulatory T cells after experimental allogeneic bone marrow transplantation. Blood, 2012, 119, 5898-5908.	1.4	114
75	Type I-IFNs control GVHD and GVL responses after transplantation. Blood, 2011, 118, 3399-3409.	1.4	64
76	Immunotherapy with Costimulatory Dendritic Cells To Control Autoimmune Inflammation. Journal of Immunology, 2011, 187, 4018-4030.	0.8	29
77	Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood, 2010, 115, 122-132.	1.4	49
78	An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood, 2010, 116, 3955-3963.	1.4	410
79	Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood, 2010, 116, 819-828.	1.4	139
80	SOCS3 regulates graft-versus-host disease. Blood, 2010, 116, 287-296.	1.4	37
81	A Physiological Function of Inflammation-Associated SerpinB2 Is Regulation of Adaptive Immunity. Journal of Immunology, 2010, 184, 2663-2670.	0.8	106
82	IFN- \hat{l}^3 Promotes Generation of IL-10 Secreting CD4+ T Cells that Suppress Generation of CD8 Responses in an Antigen-Experienced Host. Journal of Immunology, 2009, 183, 51-58.	0.8	40
83	Graft-versus-Host Disease Prevents the Maturation of Plasmacytoid Dendritic Cells. Journal of Immunology, 2009, 182, 912-920.	0.8	47
84	Induction of natural killer T cell–dependent alloreactivity by administration of granulocyte colony–stimulating factor after bone marrow transplantation. Nature Medicine, 2009, 15, 436-441.	30.7	64
85	Donor Treatment with a Multipegylated G-CSF Maximizes Graft-versus-Leukemia Effects. Biology of Blood and Marrow Transplantation, 2009, 15, 126-130.	2.0	7
86	Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies. Vaccine, 2009, 27, 3053-3062.	3.8	35
87	Invariant natural killer T cell–natural killer cell interactions dictate transplantation outcome after α-galactosylceramide administration. Blood, 2009, 113, 5999-6010.	1.4	28
88	Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. Blood, 2009, 113, 5644-5649.	1.4	79
89	Impact of cytokine gene polymorphisms on graftâ€ <i>vs</i> à€host disease. Tissue Antigens, 2008, 72, 507-516.	1.0	19
90	VCAM-1 and VLA-4 Modulate Dendritic Cell IL-12p40 Production in Experimental Visceral Leishmaniasis. PLoS Pathogens, 2008, 4, e1000158.	4.7	39

#	Article	IF	CITATIONS
91	Cutting Edge: Conventional Dendritic Cells Are the Critical APC Required for the Induction of Experimental Cerebral Malaria. Journal of Immunology, 2007, 178, 6033-6037.	0.8	104
92	Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD. Blood, 2007, 109, 5049-5057.	1.4	60
93	IFN \hat{I}^3 differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood, 2007, 110, 1064-1072.	1.4	159
94	Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?. Blood, 2006, 107, 3430-3435.	1.4	102
95	Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood, 2006, 108, 2485-2492.	1.4	121
96	Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. International Immunology, 2006, 18, 857-869.	4.0	143
97	TGF-Î ² in allogeneic stem cell transplantation: friend or foe?. Blood, 2005, 106, 2206-2214.	1.4	136
98	Cytokine Expanded Myeloid Precursors Function as Regulatory Antigen-Presenting Cells and Promote Tolerance through IL-10-Producing Regulatory T Cells. Journal of Immunology, 2005, 174, 1841-1850.	0.8	128
99	The Colony-Stimulating Factor 1 Receptor Is Expressed on Dendritic Cells during Differentiation and Regulates Their Expansion. Journal of Immunology, 2005, 175, 1399-1405.	0.8	179
100	NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. Journal of Clinical Investigation, 2005, 115, 3093-3103.	8.2	114
101	Human T lymphoblasts and activated dendritic cells in the allogeneic mixed leukocyte reaction are susceptible to NK cell-mediated anti-CD83-dependent cytotoxicity. International Immunology, 2004, 16, 33-42.	4.0	17
102	Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation. Biology of Blood and Marrow Transplantation, 2004, 10, 373-385.	2.0	26
103	Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood, 2004, 103, 3573-3581.	1.4	133
104	CMRF-44 antibody-mediated depletion of activated human dendridic cells: a potential means for improving allograft survival 1. Transplantation, 2003, 75, 1723-1730.	1.0	8
105	Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood, 2003, 101, 2033-2042.	1.4	64
106	Keratinocyte Growth Factor (KGF) in Hematology and Oncology. Current Pharmaceutical Design, 2002, 8, 395-403.	1.9	21
107	Characterization of human blood dendritic cell subsets. Blood, 2002, 100, 4512-4520.	1.4	665
108	Bitter-sweet symphony: defining the role of dendritic cell gp120 receptors in HIV infection. Journal of Clinical Virology, 2001, 22, 229-239.	3.1	29

#	ARTICLE	IF	CITATION
109	HIV gp120 receptors on human dendritic cells. Blood, 2001, 98, 2482-2488.	1.4	185
110	The role of dendritic cells in the innate immune system. Microbes and Infection, 2000, 2, 257-272.	1.9	97
111	RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 11421-11426.	7.1	61
112	Dendritic cells and the pathogenesis of rheumatoid arthritis. Journal of Leukocyte Biology, 1999, 66, 286-292.	3.3	99
113	Functional CD40 ligand is expressed by T cells in rheumatoid arthritis Journal of Clinical Investigation, 1997, 100, 2404-2414.	8.2	145
114	Neurogenesis in adult human. NeuroReport, 1996, 7, 1189-1194.	1.2	86